AstraZeneca (AZN.ST)

Close: 809.30 (+0.90), Mar 5, 2021
Negative

Medium risk

Automatic technical analysis. Medium term, Mar 5, 2021

AstraZeneca is in a falling trend channel in the medium long term. This shows that investors over time have sold at lower prices to get out of the stock, and indicates negative development for the company. The stock has support at kronor 745 and resistance at kronor 900. The stock is assessed as technically negative for the medium long term.

Recommendation one to six months: Negative (Score: -62)

Period  
Vol.bal. Volatility Liquidity +/- %
1 day-1.29%699.72+0.11%
5 days-68.224.25%873.45-0.32%
22 days-33.5910.85%715.74-3.65%
66 days-32.0820.92%744.87-9.55%

More analyses of AstraZeneca

chart AstraZeneca (AZN) Candlesticks 22 Days
Candlesticks
chart AstraZeneca (AZN) Short term
Short term: Negative
chart AstraZeneca (AZN) Medium term
Medium term: Negative
chart AstraZeneca (AZN) Long term
Long term: Hold
 


Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer. The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.


Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer. The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.

Titlex

OK